---
title: "Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Product comparison"
description: "Formulary evidence on Hibsago (bepirovirsen, GSK3228836) in Chronic hepatitis B virus infection in adults without cirrhosis: Product comparison. Topics: Bepirovirsen: class, labeled regimen, and adverse reactions; Bepirovirsen against nucleos(t)ide analogue standard of care: functional cure rates; Bepirovirsen against placebo added to continued nucleos(t)ide analogue therapy: B-Well 1 and B-Well 2; Approved therapies: HBsAg loss rates cited in reports of investigational agents; 19 further topics. 23 evidence topics quoted from 18 sources."
canonical: "https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/product-information-and-disease-description/product-comparison"
published: "2026-10-21T22:39:04-04:00"
modified: "2026-10-22T19:07:03-04:00"
---

# Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Bepirovirsen: class, labeled regimen, and adverse reactions

| Attribute | Prescribing information |
| --- | --- |
| Class | “Bepirovirsen is a synthetic, single-stranded, chimeric antisense oligonucleotide (ASO) with a gapmer architecture” |
| Combination requirement | “HIBSAGO must be used in combination with NrtI therapy.” |
| Dosage, weeks 1 and 2 | “The recommended dosage of HIBSAGO is 300 mg (administered as two 150 mg subcutaneous injections) twice a week allowing 3 or 4 days between each dose.” |
| Dosage, weeks 3 to 24 | “The recommended dosage of HIBSAGO is 300 mg (administered as two 150 mg subcutaneous injections) once a week on the same day each week.” |
| Maximum duration | “The maximum recommended duration of HIBSAGO treatment is 24 weeks” |
| Most common adverse reactions | “The most common adverse reactions (≥10%), excluding laboratory abnormalities, reported with HIBSAGO included injection site reactions, pyrexia, fatigue, and headache.” |
| Discontinuation due to adverse events | “In the pooled B-Well 1 and B-Well 2 trials, 3% of participants receiving HIBSAGO and <1% of participants receiving placebo discontinued due to adverse events.” |

Source: [Hibsago prescribing information (2026)](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Hibsago/pdf/HIBSAGO-PI-MG-IFU.PDF)

<a id="topic-2.1.2.14-2"></a>

### Bepirovirsen against nucleos(t)ide analogue standard of care: functional cure rates

> “The approval was supported by results from the B-WELL phase III trials showing functional cure rates of 19% in adults with ≤3000 IU/ml HBsAg, compared to current standard of care alone, which typically achieves less than 1% functional cure rate after one year of treatment.”

Source: [GSK press release, Hibsago US approval (2026)](https://www.gsk.com/en-gb/media/press-releases/hibsago-bepirovirsen-approved-in-the-us-for-the-treatment-of-chronic-hepatitis-b-chb/)

> “a functional cure rate of 26% (200 of 768 vs. 0 of 393 in the placebo group, with p<0.001 in both trials) was achieved in participants with ≤1000 IU/ml HBsAg level”
> “The current standard of care typically requires lifelong therapy, with functional cure rates achieved in less than 1% of patients.”

Source: [GSK press release, B-Well results (2026)](https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-achieves-unprecedented-functional-cure-rates-with-potential-to-redefine-treatment-for-chronic-hepatitis-b/)

<a id="topic-2.1.2.14-3"></a>

### Bepirovirsen against placebo added to continued nucleos(t)ide analogue therapy: B-Well 1 and B-Well 2

> “All the patients were receiving stable nucleoside or nucleotide analogue (NA) therapy and had an HBsAg level of more than 100 to 3000 IU per milliliter.”
> “The percentage of patients with a functional cure at week 72 was significantly higher with bepirovirsen than with placebo both in the B-Well 1 trial (in 127 of 650 patients [20%] vs. none of 328 patients) and in the B-Well 2 trial (in 106 of 570 patients [19%] vs. none of 286 patients).”

Source: [Hou et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/42206582/)

<a id="topic-2.1.2.14-4"></a>

### Approved therapies: HBsAg loss rates cited in reports of investigational agents

> “NAs effectively suppress HBV DNA but rarely achieve HBsAg loss (0–3% after long-term NA therapy), while IFN therapy is limited by safety and tolerability concerns”
> “Bepirovirsen has shown sustained HBsAg loss in approximately 9–10% of participants after 24 weeks of finite treatment”

Source: [Wang et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13518476/)

> “PEG-IFNα offers a finite-duration treatment with modest functional cure (<10%)”

Source: [Wong et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12823419/)

<a id="topic-2.1.2.14-5"></a>

### RNA-targeting agents in clinical development: dosing, common adverse events, and phase

| Agent | Class | Dosing | Common adverse events | Clinical trial number | Phase |
| --- | --- | --- | --- | --- | --- |
| Imdusiran (AB-729) | siRNA | “60 mg or 90 mg at varying dosing intervals (4-weekly, 8-weekly, 12-weekly) for 48 weeks” | “Injection-site reaction” | “NCT06154278” | “Phase II” |
| Xalnesiran (RG-6346) | siRNA | “Ascending dosing (1.5–6.0 mg/kg) monthly for 4 months” | “Injection-site reaction, headache” | “NCT03772249” | “Phase II” |
| Daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989) | siRNA | “Ascending dosing (25–400 mg) with varying dosing intervals (weekly, 2-weekly, 4-weekly) for 3 doses” | “Injection-site reaction, nasopharyngitis, malaise” | “NCT03365947” | “Phase II” |
| Elebsiran (VIR-2218) | siRNA | “200 mg monthly for 6 months” | “Injection-site reaction, headache” | “NCT02826018 and NCT03672188” | “Phase II” |
| RBD-1016 | siRNA | “Ascending dosing (0.3–3.0 mg/kg) at days 1 and 29” | “Injection-site reaction, headache” | “NCT05961098” | “Phase II” |
| Bepirovirsen | ASO | “300 mg or 150 mg weekly with loading dose for up to 24 weeks” | “Injection-site reaction, flu-like symptoms” | “NCT05630820” | “Phase III” |

Source: [Hui et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11750937/)

> “Dosing in latest clinical trials at the time of writing”
> “Common adverse events reported in latest clinical trials at the time of writing”

Source: [Hui et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11750937/)

<a id="topic-2.1.2.14-6"></a>

### Combination regimens with RNA-targeting agents in clinical development

| Combination | Clinical trial number | Phase |
| --- | --- | --- |
| “Imdusiran (siRNA) + Peg-IFNα” | “NCT04980482” | “Phase II” |
| “Elebsiran (siRNA) + Peg-IFNα” | “NCT04412863” | “Phase II” |
| “Bepirovirsen (ASO) + Peg-IFNα” | “NCT04676724” | “Phase II” |
| “Xalnesiran (siRNA) + ruzotolimod (Toll-like receptor 7 agonist) or Peg-IFNα” | “NCT04225715” | “Phase II” |
| “Daplusiran/tomligisiran (siRNA) + JNJ-6379 (Capsid assembly modulator)” | “NCT03982186 and NCT04129554” | “Phase II” |
| “Elebsiran (siRNA) + tobevibart (monoclonal antibody)” | “NCT04856085” | “Phase II” |

Source: [Hui et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11750937/)

<a id="topic-2.1.2.14-7"></a>

### Bepirovirsen compared with siRNAs and a GalNAc-conjugated antisense oligonucleotide: mechanism and development stage

> “Bepirovirsen is an unconjugated 20-mer ASO with a class II CpG motif that targets a conserved region in the HBV genome. Aside from its primary effect through complementary nucleotide binding, bepirovirsen can mediate TLR activity”
> “Bepirovirsen is now the only HBV RNAi therapeutic that has progressed to phase III clinical trials.”
> “The efficacy of GSK3389404 was weaker than that of bepirovirsen.”
> “The above trials demonstrated that single-agent siRNAs or ASOs cannot induce a high rate of functional cure in all patients.”

Source: [Hui et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11750937/)

<a id="topic-2.1.2.14-8"></a>

### Xalnesiran with or without an immunomodulator (Piranga phase 2): HBsAg loss 24 weeks after end of treatment

> “We conducted a phase 2, multicenter, randomized, controlled, adaptive, open-label platform trial that included the evaluation of 48 weeks of treatment with xalnesiran at a dose of 100 mg (group 1), xalnesiran at a dose of 200 mg (group 2), xalnesiran at a dose of 200 mg plus 150 mg of ruzotolimod (group 3), xalnesiran at a dose of 200 mg plus 180 μg of pegylated interferon alfa-2a (group 4), or a nucleoside or nucleotide analogue (NA) alone (group 5)”
> “Among 159 participants (30, 30, 34, 30, and 35 in groups 1 through 5, respectively), the primary end-point event occurred in 7% (95% confidence interval [CI], 1 to 22) of those in group 1, in 3% (95% CI, 0 to 17) of those in group 2, in 12% (95% CI, 3 to 28) of those in group 3, in 23% (95% CI, 10 to 42) of those in group 4, and in none (95% CI, 0 to 10) of those in group 5.”
> “HBsAg loss with or without seroconversion occurred only in participants with a screening HBsAg level below 1000 IU per milliliter.”

Source: [Hou et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39774313/)

<a id="topic-2.1.2.14-9"></a>

### Xalnesiran with or without an immunomodulator (Piranga phase 2): grade 3 or 4 adverse events

> “In groups 1 through 5, respectively, grade 3 or 4 adverse events occurred in 17%, 10%, 18%, 50%, and 6% of the participants, with the most frequent event being an elevated alanine aminotransferase level.”

Source: [Hou et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39774313/)

<a id="topic-2.1.2.14-10"></a>

### Xalnesiran-based regimens (Piranga phase 2): outcomes after nucleos(t)ide analogue discontinuation

> “Among 121 participants, 58 (48%) met NA stopping criteria and 40 (33%) discontinued NA.”
> “Among participants who remained off NA, five achieved and maintained HBsAg loss (HBsAg <0.05 IU/ml) and HBV DNA undetectable (HBV DNA <10 IU/ml); all were in treatment arms with an immunomodulator.”
> “Of the 40 participants who discontinued NA, 19 (48%) experienced virological relapse (VR), three (8%) of whom further developed clinical relapse.”

Source: [Cheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13594892/)

<a id="topic-2.1.2.14-11"></a>

### Elebsiran with pegylated interferon alfa against pegylated interferon alfa alone (ENSURE phase 2): HBsAg loss

> “In part I (cohorts 1–3), virally suppressed participants with chronic HBV infection naive to BRII-179 were randomized 1:1:1 to receive 48 weekly doses of PEG-IFNα alone or in combination with 13 doses of elebsiran (200 mg or 100 mg) administered every 4 weeks.”
> “In part I, at 24 weeks post-EOT, HBsAg loss was observed in 4 out of 19 (21.1%) participants receiving elebsiran 200 mg plus PEG-IFNα, 6 out of 18 (33.3%) participants receiving elebsiran 100 mg plus PEG-IFNα and 1 out of 18 (5.6%) participants receiving PEG-IFNα monotherapy.”
> “In part II, HBsAg loss was observed in 9 out of 31 (29.0%) participants at 24 weeks post-EOT, with a higher response among BRII-179 anti-HBs responders (8 out of 19 participants, 42.1%) compared with nonresponders (1 out of 12 participants, 8.3%).”

Source: [Wong et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12823419/)

<a id="topic-2.1.2.14-12"></a>

### Elebsiran with pegylated interferon alfa against pegylated interferon alfa alone (ENSURE phase 2): adverse events

| Event | PEG-IFNα alone (cohort 1, N = 18) | Elebsiran 200 mg plus PEG-IFNα (cohort 2, N = 19) | Elebsiran 100 mg plus PEG-IFNα (cohort 3, N = 18) |
| --- | --- | --- | --- |
| Grade 3 adverse events, n (%) | “6 (33.3)” | “6 (31.6)” | “5 (27.8)” |
| Grade 4 adverse events, n (%) | “2 (11.1)” | “0” | “1 (5.6)” |
| Serious adverse events, n (%) | “2 (11.1)” | “1 (5.3)” | “0” |

Source: [Wong et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12823419/)

> “ALT increases of grade 3 were observed in 2 of 19 (10.5%) of cohort 2 and 5.6% (1 of 18) of cohort 3 participants”

Source: [Wong et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12823419/)

<a id="topic-2.1.2.14-13"></a>

### Elebsiran with or without pegylated interferon alfa-2a (phase 2): HBsAg seroclearance and ALT elevations

> “Between July 2, 2020, and Nov 2, 2021, 124 individuals were screened for eligibility, 84 of whom were enrolled (15 in cohort 1, 15 in cohort 2, 18 in cohort 3, 18 in cohort 4, 13 in cohort 5, and five in cohort 6).”
> “Six participants (one in cohort 2, three in cohort 4, and two in cohort 5) had sustained HBsAg seroclearance through to 24 weeks after the end of treatment. No participants receiving VIR-2218 monotherapy (cohort 1) or VIR-2218 plus pegylated interferon-alfa-2a 12-week regimen (cohort 6) had HBsAg seroclearance.”
> “Two (13%) participants in cohort 1 had elevations in alanine aminotransferase, compared with 13 (87%) participants in cohort 2, 15 (83%) in cohort 3, 17 (94%) in cohort 4, 11 (85%) in cohort 5, and three (60%) in cohort 6.”

Source: [Yuen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39389081/)

<a id="topic-2.1.2.14-14"></a>

### Tobevibart with elebsiran, with or without pegylated interferon alfa (MARCH Part B): HBsAg loss and functional cure

> “Tobevibart was administered at 300 mg every 4 weeks; elebsiran, at 200 mg every 4 weeks”
> “Tobevibart and elebsiran without or with PEG-IFNα resulted in HBsAg loss 24 weeks post-end of treatment in 17% (3/18) and 21% (3/14) of participants with baseline HBsAg<1,000 IU/mL, respectively. These proportions were 8% (4/51) and 16% (5/32) for tobevibart and elebsiran without or with PEG-IFNα, respectively, in all participants.”
> “Tobevibart and elebsiran without or with PEG-IFNα resulted in functional cure in 11% (2/18) and 15% (2/13) of participants with HBsAg<1000 IU/mL, respectively. These proportions were 4% (2/51) and 10% (3/30) for the combinations without or with PEG-IFNα, respectively, in all participants.”
> “As previously communicated, Phase 3 development of combinations of tobevibart and elebsiran in CHB will not move forward without a global development and commercialization partner, which has not been secured.”

Source: [Vir Biotechnology press release (2025)](https://investors.vir.bio/news/news-details/2025/Vir-Biotechnology-Announces-Preliminary-24-Week-Post-End-of-Treatment-Data-for-Tobevibart-and-Elebsiran-Combinations-in-Chronic-Hepatitis-B-From-the-MARCH-Study/default.aspx)

<a id="topic-2.1.2.14-15"></a>

### Daplusiran/tomligisiran (JNJ-3989) with or without bersacapavir (REEF-1 phase 2b): nucleos(t)ide analogue stopping criteria

> “The primary endpoint was the proportion of patients meeting predefined nucleos(t)ide analogue-stopping criteria (alanine aminotransferase <3 × upper limit of normal, HBV DNA below the lower limit of quantitation, HBeAg negative, and HBsAg <10 IU/mL) at week 48.”
> “At week 48, five (5%; 90% CI 2-11) of 91 patients in the JNJ-3989 dual 40 mg group, 15 (16%; 10-24) of 92 in the JNJ-3989 dual 100 mg group, 18 (19%; 13-27) of 94 in the JNJ-3989 dual 200 mg group, eight (9%; 4-15) of 94 in the triple group, and one (2%; 0-10) of 45 in the control group met nucleos(t)ide analogue stopping criteria.”
> “29 (6%) of 460 patients in the treatment phase and in ten (2%) of 460 patients in the follow-up phase had grade 3 or 4 adverse events.”
> “Although treatment with JNJ-3989 led to a dose-dependent response for meeting nucleos(t)ide analogue-stopping criteria, it rarely led to HBsAg seroclearance.”

Source: [Yuen et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37442152/)

<a id="topic-2.1.2.14-16"></a>

### Daplusiran/tomligisiran (JNJ-3989) with bersacapavir (REEF-2 phase 2b): functional cure after nucleos(t)ide analogue withdrawal

> “REEF-2, a phase IIb, double-blind, placebo-controlled, randomized study, enrolled 130 nucleos(t)ide analogue (NA)-suppressed hepatitis B e-antigen (HBeAg)-negative patients with CHB”
> “At follow-up Week 24, no patients achieved the primary endpoint of functional cure (off-treatment hepatitis B surface antigen [HBsAg] seroclearance). No patients achieved functional cure at follow-up Week 48.”
> “Off-treatment HBV DNA relapse and alanine aminotransferase increases were less frequent in the active arm, with 7/77 (9.1%) and 11/41 (26.8%) patients in the active and control arms, respectively, restarting NAs during follow-up.”

Source: [Agarwal et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38583491/)

<a id="topic-2.1.2.14-17"></a>

### Daplusiran/tomligisiran (JNJ-3989) with pegylated interferon alfa-2a add-on (PENGUIN phase 2): HBsAg response and functional cure

> “In total, 48 patients (HBeAg positive, n = 11; HBeAg negative, n = 37) were enrolled; 47 reached follow-up week 48 (FUW48). Of the 48 patients, 31 (64.6%) achieved the primary endpoint; one achieved HBsAg seroclearance (<0.05 IU/ml) at both W24 and FUW48 after stopping NA.”
> “At W24, 15/48 (31.3%) patients met NA stopping criteria; 11/15 (73.3%) remained off NA by FUW48. One patient achieved functional cure at FUW48.”
> “Most patients had pronounced HBsAg reductions from baseline, no additional benefit from PegIFN-α2a, and did not achieve functional cure.”

Source: [Gane et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12409438/)

<a id="topic-2.1.2.14-18"></a>

### Imdusiran with pegylated interferon alfa-2a (IM-PROVE I phase 2a): functional cure after nucleos(t)ide analogue discontinuation

> “The IM-PROVE I study was a Phase 2a proof-of-concept study in 43 NA- suppressed, HBeAg-negative CHB subjects who received 4 doses of imdusiran (IDR) (60 mg every 8 weeks) prior to randomization to 24 weeks or 12 weeks of IFN with or without additional imdusiran doses.”
> “Six subjects in this study achieved functional cure after NA d/c; 3 additional subjects had HBV DNA <LLOQ with low HBsAg levels during NA d/c follow-up.”
> “Functional cure rates in IM-PROVE I were highest amongst subjects who received 6 doses of imdusiran (60 mg every 8 weeks) and 24 weeks of weekly IFN starting at Week 28, compared to those that received shorter courses of imdusiran (4 doses) and/or IFN (12 weeks)”
> “Significant ALT flares were not observed in the subjects that achieved FC, although IFN treatment led to asymptomatic Gr 1 to Gr 3 ALT elevations in several subjects across the study cohorts”

Source: [Yuen et al. (2025)](https://www.arbutusbio.com/wp-content/uploads/2025/05/EASL-2025_THU-260-Yuen-MF-et-al.-IM-PROVE-I_FINAL.pdf)

<a id="topic-2.1.2.14-19"></a>

### Imdusiran (AB-729-001 phase 1a/b): regimens and safety

> “These participants received subcutaneous imdusiran as a single dose of 60 mg, 90 mg, or 180 mg (part 2) or as repeat doses of 60 mg or 90 mg every 4, 8, or 12 weeks for up to 48 weeks (part 3).”
> “All 83 enrolled participants received at least one dose of imdusiran or placebo and were included in the safety analyses. Across all parts, no participants discontinued imdusiran owing to an adverse event and no dose-related trends in reported treatment-emergent adverse events were observed across groups. There were no deaths.”

Source: [Yuen et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42173110/)

<a id="topic-2.1.2.14-20"></a>

### AHB-137, an unconjugated antisense oligonucleotide (first-in-human phase 1): HBsAg loss and safety

> “Twenty-four virally suppressed, HBeAg-negative CHB patients on stable nucleos(t)ide analog therapy were enrolled”
> “Treatment-related adverse events occurred in 73% of healthy subjects and 71% of CHB patients and were primarily mild or moderate injection-site reactions and headaches. No treatment-related serious adverse events, discontinuations, or deaths were observed.”
> “HBsAg loss was achieved in 3 (15.0%) patients with very low baseline HBsAg (≤1.5 IU/mL), was maintained through the end of the study in 2 patients, and was accompanied by anti-HBs seroconversion.”
> “Functional cure could not be assessed, as nucleos(t)ide discontinuation criteria were not prespecified.”

Source: [Gane et al. (2026b)](https://doi.org/10.1097/HEP.0000000000001835)

<a id="topic-2.1.2.14-21"></a>

### Antisense oligonucleotides compared with siRNAs: HBsAg responses described in the AHB-137 first-in-human report

> “siRNA monotherapy is generally safe but has produced modest HBsAg declines (1–2 log10 IU/mL), which plateau after 16–20 weeks and are not associated with HBsAg loss. Functional cure following siRNA therapy has only been reported after sequential interferon-α therapy.”
> “In contrast, in a phase 2b study of bepirovirsen (an ASO), with or without NA, rapid HBsAg reductions were observed, with up to 26% achieving HBsAg loss at the end of treatment and 9%–10% maintaining loss after treatment cessation.”

Source: [Gane et al. (2026b)](https://doi.org/10.1097/HEP.0000000000001835)

<a id="topic-2.1.2.14-22"></a>

### AHB-137 (phase 1a/1b): structural comparison with bepirovirsen, HBsAg response, and safety

> “AHB-137 and bepirovirsen share the same target sequence but differ in pharmacological structure. Bepirovirsen follows a conventional single-gap (5–10–5) gapmer architecture with a continuous central DNA gap flanked by terminal 2′-MOE modifications, whereas AHB-137 adopts a multi-segment structural design in which the gap is divided into shorter segments separated by modified regions, with additional site-specific 2′-modifications.”
> “In Phase 1b, 20 HBeAg-negative, nucleos(t)ide analogue (NA)-suppressed CHB patients with baseline HBsAg 100–1000 IU/mL received MAD AHB-137 (150 or 300 mg) or placebo (8:2), and 2 patients with baseline HBsAg 1000–3000 IU/mL received open-label AHB-137 300 mg.”
> “No serious adverse events, deaths or discontinuations occurred.”
> “Transaminase elevations were self-limiting; one Grade 3 ALT elevation in the 300 mg CHB cohort coincided with rapid HBsAg loss.”
> “cross-trial comparisons should be interpreted with caution due to the differences in baseline HBsAg range, sample size, and study design.”

Source: [Wang et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13518476/)

<a id="topic-2.1.2.14-23"></a>

### VRON-0200 therapeutic vaccine alone or followed by elebsiran plus tobevibart (phase 1b): HBsAg declines and safety

> “This phase 1b, randomised, open-label, multicentre trial included participants with chronic HBV infection aged between 18 and 55 years who had normal liver function, were receiving stable nucleos(t)ide therapy, and had non-detectable HBV DNA for 12 months or more.”
> “VRON-0200 was well tolerated, with 38 treatment-related adverse events reported (four of grade 2, 34 of grade 1); no treatment-related serious adverse events, discontinuations, or clinical laboratory abnormalities, including liver function test results, were reported.”
> “In groups 1 and 2, at day 360, 23 (85%) of 27 participants had sustained or continued HBsAg declines (12 [52%] of 23 had reductions of >50%) and four (15%) participants had declines of 1 log10 IU/mL or more from baseline.”
> “In group 3, the addition of investigational antivirals resulted in rapid and profound HBsAg declines within 7 days (all seven [100%] participants treated with elebsiran plus tobevibart had HBsAg concentrations <2 IU/mL; one [14%] had HBsAg concentrations below the LLOD), regardless of baseline HBsAg concentrations.”

Source: [Gane et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/42214405/)

## Related pages
- [Hibsago (bepirovirsen): Chronic hepatitis B virus infection in adults without cirrhosis](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Terms and abbreviations](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/terms-and-abbreviations.md)
- [Hibsago (bepirovirsen): Chronic hepatitis B virus infection in adults without cirrhosis](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/executive-summary.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Product information and disease description](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/product-information-and-disease-description.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Clinical evidence](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/clinical-evidence.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Economic information and modeling report](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/economics) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/economics.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: References](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/references) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/references.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: new drug review](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/monograph/review) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/monograph/review.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/cost-effectiveness-analyses.md)